Prices and Markets

Geiger Counter – Supply deficit unsustainable

2018 saw a strong recovery in the uranium price. This has stalled this year, but with the uranium market now seeing more demand than supply, Geiger Counter’s (GCL’s) managers see the potential for a resurgence in the uranium price, as more nuclear reactors come online (particularly in China and India), while major producers hold off from returning mothballed mines to production…. Read more

An announcement by the Trump administration in July, in relation to its section 232 investigation into the uranium security of supply, has created uncertainty for US-based customers. They are unsure whether there might be import quotas, for example – see page 3). This has put a break on purchases and is suppressing the uranium price. However, it is also leading to significant pent-up demand, creating the potential for a sharp reversal of the uranium price once things are clarified. The managers see the current situation as unsustainable.

Capital growth from a diversified global portfolio of uranium stocks

GCL aims to provide investors with capital growth by investing in a portfolio of securities of companies involved in the exploration, development and production of energy, as well as related service companies. Its main focus is the uranium sector, but up to 30% of assets can be invested in other resource-related companies. These include, but are not limited to, shares, convertibles, fixed-income securities and warrants.

Read more

NB: Marten & Co was paid to produce this note on Geiger Counter Limited and it is for information purposes only. It is not intended to encourage the reader to deal in the
security or securities mentioned in this report. Please read the important information at the back of this note. QuotedData is a trading name of Marten & Co Limited which
is authorised and regulated by the FCA. Marten & Co is not permitted to provide investment advice to individual investors categorised as Retail Clients under the rules of
the Financial Conduct Authority.

Edward Marten

Edward Marten is MD of investor research company QuotedData. They provide free information for investors who find it hard to access high-quality, reliable, equity research on UK and European-listed companies. This is a QuotedData release.

Published by